ClinicalTrials.gg
RecruitingNCT07148843Updated Nov 3, 2026

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

A Phase 2/3 interventional study of Cannabidiol (CBD) and Placebo in Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification and Craving, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Johns Hopkins University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 3, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing cannabidiol in Alcoholism — 4 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Alcoholism.

Planned enrollment
4th of 12
105 · median 49
Started
2026
with 1 other
Phase 2/3
2 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Johns Hopkins University

Among the 12 studies testing cannabidiol in Alcoholism, this one is the 4th largest by planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 2/3, and was the 11th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies testing cannabidiol in Alcoholism are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cannabidiol in Alcoholism, or all of them as a file.
02

Study summary

Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.

Read the detailed description

Alcohol withdrawal during acute abstinence represents a major health threat to millions of individuals struggling with alcohol use disorder (AUD): it has been associated with complications in patients admitted for medically supervised withdrawal including seizures and delirium tremens (the latter of which can be fatal if not managed appropriately) and can interfere with treatment efforts. Benzodiazepines, such as lorazepam (Ativan) represent the first-line treatments for control of alcohol withdrawal, yet higher doses of benzodiazepines required to manage more complicated withdrawal cases increase risk of respiratory depression and delirium. Furthermore, a growing frequency of benzodiazepine shortages (at least 20 shortages within the previous ten years lasting a median of 244 days) necessitates a need for alternative and adjunctive medications. Preclinical animal trials involving cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) have shown its use is associated with statistically significant reductions in withdrawal symptoms and there is evidence in non-AUD populations that CBD is effective in reducing anxiety, insomnia, and seizures, which are all symptoms of alcohol withdrawal. The capacity for CBD to enhance the effect of the inhibitory neurotransmitter Gama-aminobutyric acid (GABA) in a manner akin to benzodiazepines has also been demonstrated. Collectively this information suggests that CBD could alleviate signs and symptoms of alcohol withdrawal, and subsequently reduce the need for adjunctive benzodiazepines.

This randomized placebo-controlled clinical trial will enroll adults with moderate-to-severe AUD who will be admitted to an inpatient research unit at the Johns Hopkins Hospital for management of their alcohol withdrawal. Enrolled participants with a history of alcohol withdrawal symptoms will be randomized to receive an oral formulation of either placebo or one of two CBD doses (10 mg/kg or 20 mg/kg). These doses have been well-studied and tolerated in prior studies and clinical trials for other disorders. Alcohol withdrawal symptoms, as defined by Diagnostic and Statistical Manual (DSM-5) criteria, will be assessed by nursing administration of the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) and participant completion of the Alcohol Withdrawal Symptom Checklist (AWSC). The CIWA-Ar scale will be used to guide the administration of symptom-triggered lorazepam (trade name Ativan) for all participants. As insomnia is a DSM-5 criterion for alcohol withdrawal, sleep quality will be assessed by completion of the Consensus Sleep Diary (CSD) and wrist actigraphy. Last, since cravings correlate closely with withdrawal symptoms and CBD has been observed to reduce craving for other substances, we will explore CBD's impact on alcohol craving by having participants complete the Alcohol Urge Questionnaire throughout the study. In short, the goals of this study will be to (1) determine the effect of CBD on physiologic and subjective symptoms of alcohol withdrawal, (2) determine the capacity of CBD to improve insomnia and disordered sleep during withdrawal, and (3) determine if CBD can attenuate alcohol cravings during acute abstinence.

Results from this study can help inform the possible use of CBD as a novel adjunct treatment for alcohol withdrawal and cravings that may reduce benzodiazepine need for alcohol withdrawal treatment. If CBD is shown to be effective, this line of work also points to the potential of the endogenous cannabinoid system playing a mechanistic role in alcohol's withdrawal symptoms. Finally, this study could provide further insights into the efficacy of CBD as a sleep agent for participants with alcohol withdrawal and lay the groundwork for subsequent studies exploring CBD's use in the treatment of alcohol withdrawal in an outpatient setting.

03

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Withdrawal From Addictive Substance; Detoxification
  • Craving

Keywords

  • alcohol abstinence
  • alcohol withdrawal treatment
  • detoxification
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria Moderate or Severe Alcohol Use Disorder
  • Age 21-65
  • Report at least one prior episode of alcohol withdrawal symptoms at least one day in duration that caused significant impairment in functioning (i.e., unable to attend work or engage in typical activities) AND/OR required medications to manage symptoms.
  • Report at least 21 days of heavy drinking (four or more drinks for women, five or more drinks for men) over the last 28 days.
  • if female of who has not had a sterilization procedure:
  • Negative human chorionic gonadotropin (hCG) on qualitative urine pregnancy screen
  • Agree to use a highly effective method of (e.g. hormonal contraception, intrauterine device, double-barrier method) for at least five days prior to administration of the study drug and throughout the duration of the study
  • Shipley vocabulary score > 18, corresponding to 5th grade reading level.
  • Demonstrated understanding of and ability to consent to participation in the study.

Exclusion criteria

Exclusion Criteria

  • Current or past alcohol-related medical complications including but not limited to cirrhosis of the liver, esophageal varices, pancreatitis, severe gastritis, hemoptysis, hematochezia, or melena.
  • Use of gabapentin, benzodiazepines, or other sedative-hypnotic medications within the week prior to admission
  • Regular use (i.e. twice a week or more) of CBD-dominant products, including Epidiolex®, within the last three months
  • Regular use of benzodiazepines (e.g., twice a week or more) within the last three months
  • Meet criteria for moderate-to-severe substance use disorder (SUD), including moderate-to-severe Cannabis Use Disorder (except for alcohol- and tobacco-related disorders)
  • •Urine drug screen indicating the presence of substances other than cannabis at screening.
  • Active suicidal ideation or recent suicide attempts (e.g. within six months)
  • Unstable and/or compromising medical or psychiatric conditions that would interfere with participant safety as determined by study physician.
  • Current pregnancy
  • \<18.5 kg/m2
  • History of anorexia nervosa or bulimia in the past 2 years
  • History of seizures or seizure disorder outside of alcohol-withdrawal related seizures
  • History of complicated alcohol withdrawal (e.g. seizures, delirium tremens) as verified by medical record review if available
  • Mean systolic blood pressure (SBP) >/= 140 mm Hg, DBP >/= 90 mmHg or pulse >/= 110 mm Hg during screening
  • Mean systolic blood pressure (SBP) >/=160 mm Hg, DBP>/=110 mm Hg, or pulse >/=120 mm Hg during pre-admission at Behavioral Pharmacology Research Unit (BPRU) prior to admission to CRU
  • Any of the following laboratory values during screening or upon admission:

    • > 165 U/L (normal range 19-55)
    • ALT > 216 U/L (normal range 19-72)
    • Alkaline phosphatase > 1.5x (ULN) (normal range 38-126)
    • Total >1.5 ULN (normal values=0.3-1.0 mg/dL)
    • Non-fasting glucose > 250 mg/ml (normal range 65-179)
    • Hematocrit \< 38 % (normal range 41-53)
    • \< 12 g/dl (normal range 13.5-17.5) or any other laboratory value significantly outside the normal range
  • Use of a prescription medication (except for prescriptions) within 14 days of study entry, which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. This includes any medication in which CYP2C9, CYP2C19, CYP1A2, CYP2B10, or enzymes are major metabolizers. Participants taking medications that are substrates of UDP-glucuronosyltransferase 1-9 (UGT1A9), UDP-glucuronosyltransferase 2B7 (UGT2B7), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or P-gp wll be allowed into the study but closely monitored for potential adverse events based on the prescribing information of the concomitant medications given CBD's potential to inhibit these enzymes.
  • Use of prescription medications, OTC medications, herbal medications, and/or dietary supplements that are strong inducers of CYP3A4 or CYP2C19 within 14 days or 5 half-lives (whichever is longer) prior to study drug administration
  • with -corrected interval (QTc) > 450 ms and/or presence of abnormality
  • Participation in other clinical trials within the past 60 days
  • Court-mandated participation in alcohol treatment or pending incarceration.
  • Known chronic liver disease or cirrhosis of any etiology (e.g. , infections, Metabolic Dysfunction-Associated Steatohepatitis [MASH]]) except in the following cases: 1. Fully resolved infection (HBsAg negative, anti- core antibody (anti-HBc) and/or anti-Hepatitis B surface antibody (anti-HBs) positive, with normal liver function tests) or 2. Successfully treated hepatitis C infection (HCV RNA negative, with normal liver function tests and no evidence of advanced fibrosis or cirrhosis)
  • Recent acute hepatitis of any etiology (e.g. drug-induced hepatitis, hepatitis A infection within the past six months)
  • Moderate to severe hepatic impairment ( Class B and C)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Active comparator
    10 mg/kg CBD

    low dose CBD

    Drug: Cannabidiol (CBD)

  • Active comparator
    20 mg/kg CBD

    high dose CBD

    Drug: Cannabidiol (CBD)

  • Placebo comparator
    placebo

    Placebo (no CBD)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Peak score on the Alcohol Withdrawal Symptom Checklist (AWSC)

    The Alcohol Withdrawal Symptom Checklist (AWSC) is a validated measure in which participants report their own withdrawal symptoms. The scale consists of 17 items. The total possible score is 0-68, with higher scores indicating more severe withdrawal symptoms. The highest score for a participant across the duration of their time on the Clinical Research Unit (CRU) will be included in the analysis.

    Time frame: Four times daily during inpatient stay (4 nights)

  2. Peak score on the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar)

    The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) is a clinically administered measurement that represents the gold standard for assessing the severity of withdrawal symptoms. It consists of 10-items: nausea/ vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation/clouding of sensorium. Each sign and symptom is rated on a Likert scale from 0-7 (with 0=absent and 7 =most severe), except for "clouding of sensorium," which is ranked from 0 to 4. Scores on the CIWA-Ar scale range from 0 to 67, with higher scores indicating more severe withdrawal. The highest score for a participant across the duration of their time on the CRU will be included in the analysis. Clinical staff will use these scores to justify administration of benzodiazepines to treat withdrawal symptoms.

    Time frame: 4 times daily during inpatient stay (4 nights)

  3. Average total sleep time (minutes) and wake after sleep onset as measured by wrist actigraphy

    Actigraphy will provide a primary assessment of sleep outcomes including total sleep time and wake after sleep onset. The actigraphy devices used will be triaxial accelerometers from Generation model 9 (GT9X) Link Wrist Actigraphy, Actigraph LLC. Values for total sleep time and wake time after sleep onset will be averaged across the study's four nights; this average will be included in the analysis.

    Time frame: 4 nights during inpatient stay

  4. Peak alcohol craving as measured by scores on the Alcohol Urge Questionnaire (AUQ)

    The Alcohol Urge Questionnaire (AUQ) is an eight-item self-report questionnaire that has demonstrated validity and discriminative value in identifying and measuring alcohol craving. Each item is ranked on a score of 0 to 7, with a maximum score range of 0- 56. Higher scores indicate greater craving. The highest score for a participant across the duration of their time on the CRU will be included in the analysis.

    Time frame: Four times daily during inpatient stay (4 nights)

Secondary outcomes

  1. Average Total Sleep Time (minutes) as reported in Consensus Sleep Diary (CSD) results

    The Consensus Sleep Diary (CSD) is a standardized subjective sleep rating measure in which participants rate features of their sleep-average total sleep time. Generally higher number is better.

    Time frame: Upon waking each morning during inpatient stay (4 days)

  2. Total Amount of Time (minutes) on Awakenings, as reported in Consensus Sleep Diary (CSD) results

    The Consensus Sleep Diary (CSD) is a standardized subjective sleep rating measure in which participants rate features of their sleep- total amount of time on awakenings. Higher number indicating more awakenings (worse).

    Time frame: Upon waking each morning during inpatient stay (4 days)

  3. Sleep Quality as reported in Consensus Sleep Diary (CSD) results

    The Consensus Sleep Diary (CSD) is a standardized subjective sleep rating measure consisting of nine items in which participants rate features of their sleep--sleep quality either "Very Poor," "Poor," "Fair," "Good," or "Very Good"

    Time frame: Upon waking each morning during inpatient stay (4 days)

  4. Sleep Latency (minutes) as reported in Consensus Sleep Diary (CSD) results

    The Consensus Sleep Diary (CSD) is a standardized subjective sleep rating measure consisting of nine items in which participants rate features of their sleep - sleep latency (how long it takes one to fall asleep). Higher values would indicate worse sleep latency.

    Time frame: Upon waking each morning during inpatient stay (4 days)

  5. Number of Awakenings as reported in Consensus Sleep Diary (CSD) results

    The Consensus Sleep Diary (CSD) is a standardized subjective sleep rating measure consisting of nine items in which participants rate features of their sleep--number of awakenings. Higher number indicating more awakenings (worse).

    Time frame: Upon waking each morning during inpatient stay (4 days)

  6. Total amount of time (minutes) spent awake after sleep onset as reported in Consensus Sleep Diary (CSD) results

    The Consensus Sleep Diary (CSD) is a standardized subjective sleep rating measure consisting of nine items in which participants rate features of their sleep-- total amount of time spent awake after sleep onset. higher values indicating more time awake (worse).

    Time frame: Upon waking each morning during inpatient stay (4 days)

  7. Total doses of lorazepam administered

    Lorazepam (trade name: Ativan) is a benzodiazepine that is frequently used in clinical practice to manage alcohol withdrawal symptoms. Since the decision to administer lorazepam is guided by CIWA scores, it can serve as a proxy for severity of withdrawal symptoms. Every four hours daily as needed for CIWA scores \>/=10 while the participant stays on the inpatient Johns Hopkins Hospital (JHH) CRU

    Time frame: Every 4 hours during inpatient stay (4 nights)

  8. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are enzymes that act as proxies for hepatic function and damage. Elevations in the serum levels (U/L) of these enzymes--particular at levels \>/= 3 times the upper limit of normal--can indicate liver injury.

    Time frame: Morning prior to admission, morning of discharge (day 5)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Oct 2030, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 29, 2025
StartActual
Oct 21, 2026
Primary completionEst.
Oct 31, 2030
CompletionEst.
Oct 31, 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
Behavioral Pharmacology Research Unit is now Recruiting
Oct 2, 2026
Start date
Oct 1, 2026→Oct 21, 2026 (actual)
moved 2 times, Oct 2, 2026 – Nov 3, 2026
Eligibility
3 inclusion criteria added, 1 removed; 9 exclusion criteria edited, 7 added
What changed in the criteria
Inclusion criteria
  • RemovedDrinking at least 8 drinks a day over the two weeks prior to screening.
  • AddedReport at least 21 days of heavy drinking (four or more drinks for women, five or more drinks for men) over the last 28 days.
  • Addedif female of childbearing potential who has not had a sterilization procedure:
  • AddedAgree to use a highly effective method of contraception (e.g. hormonal contraception, intrauterine device, double-barrier method) for at least five days prior to administration of the study drug and throughout the duration of the study
Exclusion criteria
  • EditedRegular use (i.e.g., more than twice a week or more) of cannabis or CBD-dominant products., including Epidiolex®, within the last three months
  • EditedMeet DSM-5 criteria for moderate-to-severe substance use disorder (SUD), including moderate-to-severe Cannabis Use Disorder (except for alcohol- and tobacco-related disorders)
  • Edited•Urine drug screen indicating the presence of substances other than cannabis at screening.
  • AddedActive suicidal ideation or recent suicide attempts (e.g. within six months)
  • ChangedBefore BMI <17Now BMI <18.5 kg/m2
  • AddedHistory of complicated alcohol withdrawal (e.g. seizures, delirium tremens) as verified by medical record review if available
  • EditedSystolicMean systolic blood pressure (SBP) > 180/= 140 mm Hg, Diastolic Blood Pressure (DBP) > 120/= 90 mmHg or pulse > 120/= 110 mm Hg during screening or upon admission
  • AddedMean systolic blood pressure (SBP) >/=160 mm Hg, DBP>/=110 mm Hg, or pulse >/=120 mm Hg during pre-admission at Behavioral Pharmacology Research Unit (BPRU) prior to admission to CRU
  • EditedAlkaline phosphatase > 378 U/L1.5x upper limit of normal (ULN) (normal range 38-126)
  • EditedTotal bilirubin >21.5 mg/dlULN (normal values=0.3-1.0 mg/dL)
  • EditedUse of a prescription medication (except for birth control prescriptions) within 14 days of study entry, which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. This includes any medication in which CYP2C9, CYP2C19, CYP1A2, CYP2B10, or CYP3A4 enzymes are major metabolizers. Participants taking medications that are substrates of UDP-glucuronosyltransferase 1-9 (UGT1A9), UDP-glucuronosyltransferase 2B7 (UGT2B7), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or P-gp wll be allowed into the study but closely monitored for potential adverse events based on the prescribing information of the concomitant medications given CBD's potential to inhibit these enzymes.
  • AddedUse of prescription medications, OTC medications, herbal medications, and/or dietary supplements that are strong inducers of CYP3A4 or CYP2C19 within 14 days or 5 half-lives (whichever is longer) prior to study drug administration
  • EditedECG with QT-corrected QT interval (QTCQTc) >/= 500 450 ms and/or presence of clinically significant abnormality
  • AddedKnown chronic liver disease or cirrhosis of any etiology (e.g. autoimmune, infections, Metabolic Dysfunction-Associated Steatohepatitis [MASH]]) except in the following cases: 1. Fully resolved hepatitis B infection (HBsAg negative, anti-Hepatitis C core antibody (anti-HBc) and/or anti-Hepatitis B surface antibody (anti-HBs) positive, with normal liver function tests) or 2. Successfully treated hepatitis C infection (HCV RNA negative, with normal liver function tests and no evidence of advanced fibrosis or cirrhosis)
  • AddedRecent acute hepatitis of any etiology (e.g. drug-induced hepatitis, hepatitis A infection within the past six months)
  • AddedModerate to severe hepatic impairment (Child-Pugh Class B and C)
Oct 2, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionAverage total sleep time (minutes) and wake after sleep onset as measured by wrist actigraphy: how it is measured was reworded
Oct 2, 2026
Show all 2 updates
  1. Nov 3, 2026
    Start date Nov 1, 2026→Oct 21, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 2, 2026
    Not yet recruiting→Recruiting
    Behavioral Pharmacology Research Unit is now Recruiting
    Start date Oct 1, 2026→Nov 1, 2026
    Eligibility 3 inclusion criteria added, 1 removed; 9 exclusion criteria edited, 7 added
    What changed in the criteria
    Inclusion criteria
    • RemovedDrinking at least 8 drinks a day over the two weeks prior to screening.
    • AddedReport at least 21 days of heavy drinking (four or more drinks for women, five or more drinks for men) over the last 28 days.
    • Addedif female of childbearing potential who has not had a sterilization procedure:
    • AddedAgree to use a highly effective method of contraception (e.g. hormonal contraception, intrauterine device, double-barrier method) for at least five days prior to administration of the study drug and throughout the duration of the study
    Exclusion criteria
    • EditedRegular use (i.e.g., more than twice a week or more) of cannabis or CBD-dominant products., including Epidiolex®, within the last three months
    • EditedMeet DSM-5 criteria for moderate-to-severe substance use disorder (SUD), including moderate-to-severe Cannabis Use Disorder (except for alcohol- and tobacco-related disorders)
    • Edited•Urine drug screen indicating the presence of substances other than cannabis at screening.
    • AddedActive suicidal ideation or recent suicide attempts (e.g. within six months)
    • ChangedBefore BMI <17Now BMI <18.5 kg/m2
    • AddedHistory of complicated alcohol withdrawal (e.g. seizures, delirium tremens) as verified by medical record review if available
    • EditedSystolicMean systolic blood pressure (SBP) > 180/= 140 mm Hg, Diastolic Blood Pressure (DBP) > 120/= 90 mmHg or pulse > 120/= 110 mm Hg during screening or upon admission
    • AddedMean systolic blood pressure (SBP) >/=160 mm Hg, DBP>/=110 mm Hg, or pulse >/=120 mm Hg during pre-admission at Behavioral Pharmacology Research Unit (BPRU) prior to admission to CRU
    • EditedAlkaline phosphatase > 378 U/L1.5x upper limit of normal (ULN) (normal range 38-126)
    • EditedTotal bilirubin >21.5 mg/dlULN (normal values=0.3-1.0 mg/dL)
    • EditedUse of a prescription medication (except for birth control prescriptions) within 14 days of study entry, which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. This includes any medication in which CYP2C9, CYP2C19, CYP1A2, CYP2B10, or CYP3A4 enzymes are major metabolizers. Participants taking medications that are substrates of UDP-glucuronosyltransferase 1-9 (UGT1A9), UDP-glucuronosyltransferase 2B7 (UGT2B7), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or P-gp wll be allowed into the study but closely monitored for potential adverse events based on the prescribing information of the concomitant medications given CBD's potential to inhibit these enzymes.
    • AddedUse of prescription medications, OTC medications, herbal medications, and/or dietary supplements that are strong inducers of CYP3A4 or CYP2C19 within 14 days or 5 half-lives (whichever is longer) prior to study drug administration
    • EditedECG with QT-corrected QT interval (QTCQTc) >/= 500 450 ms and/or presence of clinically significant abnormality
    • AddedKnown chronic liver disease or cirrhosis of any etiology (e.g. autoimmune, infections, Metabolic Dysfunction-Associated Steatohepatitis [MASH]]) except in the following cases: 1. Fully resolved hepatitis B infection (HBsAg negative, anti-Hepatitis C core antibody (anti-HBc) and/or anti-Hepatitis B surface antibody (anti-HBs) positive, with normal liver function tests) or 2. Successfully treated hepatitis C infection (HCV RNA negative, with normal liver function tests and no evidence of advanced fibrosis or cirrhosis)
    • AddedRecent acute hepatitis of any etiology (e.g. drug-induced hepatitis, hepatitis A infection within the past six months)
    • AddedModerate to severe hepatic impairment (Child-Pugh Class B and C)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionAverage total sleep time (minutes) and wake after sleep onset as measured by wrist actigraphy: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07148843
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Oct 21, 2026
Primary completion
Oct 31, 2030 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

David Woliinsky, MD
Contact
dwolins2@jhmi.edu
(410) 550-0047
Elise M Weerts, PhD
Contact
eweerts@jhmi.edu
410-550-2781
David Woliinsky, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion